NCT05696067 is a Phase 1, PHASE2 clinical trial of Corfluvec component 1 low dose in COVID-19, sponsored by Tatyana Zubkova.

Who is sponsoring NCT05696067?

NCT05696067 is sponsored by Tatyana Zubkova.

What drugs are being tested in NCT05696067?

Interventions in NCT05696067: Corfluvec component 1 low dose, Corfluvec component 2 low dose, Corfluvec component 1 high dose, Corfluvec component 2 high dose, Corfluvec low dose, Corfluvec high dose, Placebo.

Is NCT05696067 still recruiting?

NCT05696067 is currently completed. Last updated 18 April 2024.

Last reviewed 2024-04-18 · How we verify

NCT05696067

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers

Completed Phase 1, PHASE2 Last updated 18 April 2024

What this trial tests

Phase 1, PHASE2 trial testing Corfluvec component 1 low dose in COVID-19 in 200 participants. Completed in 31 May 2023.

Timeline

13 September 2022

Primary endpoint
30 December 2022

31 May 2023

Quick facts

Lead sponsor	Tatyana Zubkova
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	200
Start date	13 September 2022
Primary completion	30 December 2022
Estimated completion	31 May 2023
Sites	2 locations across Russia

Drugs / interventions tested

Corfluvec component 1 low dose — full drug profile →
Corfluvec component 2 low dose — full drug profile →
Corfluvec component 1 high dose — full drug profile →
Corfluvec component 2 high dose — full drug profile →
Corfluvec low dose — full drug profile →
Corfluvec high dose
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Tatyana Zubkova — full company profile →

Who can join

Adults 18 to 60, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to investigate the safety and immunogenicity of a two-component intranasal vaccine for the prevention of COVID-19 in healthy volunteers 18-60 years old

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Vaccine adjuvants for infectious disease in the clinic.
Goetz M, Thotathil N, Zhao Z, Mitragotri S. · · 2024 · cited 29× · PMID 39036089 · DOI 10.1002/btm2.10663
The Role of Mucoadhesion and Mucopenetration in the Immune Response Induced by Polymer-Based Mucosal Adjuvants.
Vasquez-Martínez N, Guillen D, Moreno-Mendieta SA, Sanchez S, et al · · 2023 · cited 26× · PMID 37050229 · DOI 10.3390/polym15071615
Overview of Nucleocapsid-Targeting Vaccines against COVID-19.
Rak A, Isakova-Sivak I, Rudenko L. · · 2023 · cited 15× · PMID 38140214 · DOI 10.3390/vaccines11121810
Truncated NS1 Influenza A Virus Induces a Robust Antigen-Specific Tissue-Resident T-Cell Response and Promotes Inducible Bronchus-Associated Lymphoid Tissue Formation in Mice.
Shurygina AP, Shuklina M, Ozhereleva O, Romanovskaya-Romanko E, et al · · 2025 · cited 2× · PMID 39852837 · DOI 10.3390/vaccines13010058
Mucosal Immunization with an Influenza Vector Carrying SARS-CoV-2 N Protein Protects Naïve Mice and Prevents Disease Enhancement in Seropositive Th2-Prone Mice.
Sergeeva MV, Vasilev K, Romanovskaya-Romanko E, Yolshin N, et al · · 2024 · cited 2× · PMID 39852794 · DOI 10.3390/vaccines13010015
SARS-CoV-2 and Influenza Co-Circulation and Co-Vaccination: A Narrative Review.
Kamransarkandi M, Varyushina EA, Gorshkov AN, Stukova MA. · · 2026 · PMID 41893818 · DOI 10.3390/vaccines14030283

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Tatyana Zubkova trials

Trials by the same sponsor.

NCT05970744 — Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Year · Phase 1 · completed
NCT05945498 — Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Ye · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05696067 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tatyana Zubkova
Last refreshed: 18 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05696067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing